Literature DB >> 2306417

Evidence for the polymorphic oxidation of debrisoquine in the Thai population.

S Wanwimolruk1, P Patamasucon, E J Lee.   

Abstract

Debrisoquine polymorphism has been studied extensively in Caucasian populations. The prevalence of the poor metaboliser phenotype is 3-10% in European and American Caucasian populations but appears to be very low in Asian populations. This study was carried out to determine the metabolic oxidation status in 173 Thai subjects. Phenotyping was performed using the metabolic ratio (MR) calculated as the 0-8 h urinary output of debrisoquine/0-8 h urinary output of 4-hydroxydebrisoquine after oral administration of 10 mg debrisoquine hemisulphate. Two subjects (1.2%) were phenotyped as poor metabolisers; they had MR values of 13.17 and 92.04. The incidence of the poor metaboliser phenotype of debrisoquine oxidation of 1.2% seems to be lower in the Thai population compared with that in various Caucasian populations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306417      PMCID: PMC1380091          DOI: 10.1111/j.1365-2125.1990.tb03627.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Measurement of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.

Authors:  E J Lee; S B Ang
Journal:  J Pharm Biomed Anal       Date:  1987       Impact factor: 3.935

2.  Low frequency of slow debrisoquine hydroxylation in a native Chinese population.

Authors:  Y C Lou; L Ying; L Bertilsson; F Sjöqvist
Journal:  Lancet       Date:  1987-10-10       Impact factor: 79.321

Review 3.  Ethnic differences in drug metabolism.

Authors:  W Kalow
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

4.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors:  K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

Review 5.  Defective oxidation of drugs: pharmacokinetic and therapeutic implications.

Authors:  M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

6.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

7.  Ethnic difference in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals.

Authors:  W Kalow; S V Otton; D Kadar; L Endrenyi; T Inaba
Journal:  Can J Physiol Pharmacol       Date:  1980-09       Impact factor: 2.273

8.  Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.

Authors:  M Eichelbaum; N Spannbrucker; B Steincke; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1979-09       Impact factor: 2.953

9.  Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.

Authors:  A Küpfer; R Preisig
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population.

Authors:  S I Islam; J R Idle; R L Smith
Journal:  Xenobiotica       Date:  1980-11       Impact factor: 1.908

View more
  4 in total

1.  Genetic polymorphism of CYP2D6 in a keralite (South India) population.

Authors:  B K Abraham; C Adithan; C H Shashindran; S Vasu; N A Alekutty
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

2.  Polymorphism of debrisoquine oxidation in New Zealand Caucasians.

Authors:  S Wanwimolruk; J R Denton; D G Ferry; M Beasley; J R Broughton
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  Evidence for the polymorphic oxidation of debrisoquine and proguanil in a Khmer (Cambodian) population.

Authors:  S Wanwimolruk; M R Thou; D J Woods
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

4.  Cytochrome P450 2D6 polymorphism in eastern Indian population.

Authors:  Monalisa Dhuya; Murari Mohan Pal; Avijit Hazra; Suparna Chatterjee; Nithya Gogtay
Journal:  Indian J Pharmacol       Date:  2020-08-04       Impact factor: 1.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.